Project Grant R01CA299328
Award Date 4/1/26
Completion Date 3/31/31
Dollars Obligated $357K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
- Federal Grant Award Summary Oregon Health & Science University received a $625,179 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) awarded on March 26, 2026, with completion targeted for February 28, 2031. The award funds research aimed at developing direct and indirect targeting strategies of the MCL1 (myeloid cell leukemia-1) protein to improve therapeutic outcomes for osteosarcoma patients with lung metastasis. The...
- Federal Project Grant Award Summary The National Cancer Institute awarded Oregon Health & Science University (OHSU) a Project Grant totaling $521,002 under the Cancer Biology Research program (CFDA 93.396) on March 26, 2026, with a completion date of February 28, 2031. This award funds the development and application of a microphysiological bone metastasis-on-a-chip platform designed to advance understanding of prostate cancer metastasis to bone tissue. The research deliverables include an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Oregon Health & Science University a $2.27 million Project Grant under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, with completion targeted for August 31, 2029. This award supports fundamental research investigating androgen receptor (AR) signaling in conventional dendritic cells (CDCs) and its role in sex-based differences in anti-tumor immune function, particularly in melanoma....
- Federal Project Grant Award Summary Oregon Health & Science University received a $2.49 million Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on August 15, 2025, with a completion date of July 31, 2029. The award supports development and validation of fluorescence-guided surgery (FGS) technology to enable real-time nerve visualization during colorectal cancer surgical procedures. The project addresses a...
- Federal Project Grant Award Summary The National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) awarded a $164,000 Project Grant to The University of Texas MD Anderson Cancer Center, effective September 1, 2025, through August 31, 2027. This award supports research investigating the clonal determinants of platinum/PARP inhibitor (PARPi) cross-resistance in high-grade serous ovarian cancer (HGSOC). The research utilizes a novel somatic mosaic genetically-engineered mouse model...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $109,076 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective January 16, 2026, with an ultimate completion date of July 15, 2029. The grant supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. OHSU will conduct research investigating the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $483,343.83 to the University of New Mexico Health Sciences Center on May 7, 2025, under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on the regulation of ovarian cancer metastasis. The research project, which extends through November 30, 2030, investigates how microenvironmental signals activate the transcription factor C-JUN in ovarian cancer cells and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Alabama a $631,621 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated top-down proteomics and phosphoproteomics platform for analyzing patient-derived ovarian cancer spheroids. The award, effective August 13, 2025, through July 31, 2028, supports the creation of personalized intact proteome maps that characterize disease states and identify markers...
- Federal Project Grant Award Summary The National Cancer Institute awarded $593,338 to The University of Texas Health Science Center at San Antonio under the Cancer Treatment Research program (CFDA 93.395) on March 25, 2026, for the development of first-in-class AP2 associated kinase 1 (AAK1) proteolysis-targeting chimeras (PROTACs) targeting ovarian cancer treatment resistance. The project, extending through February 28, 2031, addresses a critical clinical challenge in ovarian cancer therapy:...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...